Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cell.2020.06.044 http://scihub22266oqcxt.onion/10.1016/j.cell.2020.06.044 32673567!7355337!32673567     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell 2020 ; 182 (4): 843-854.e12 Nephropedia Template TP {{tp|p=32673567|t=2020. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients |pdf=|usr=}}{{32673567}} gab.com Text Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients JO: Cell http://www.kidney.de/pget.php?&tw=1&pmid=32673567 #FOAvip The SARS-CoV-2 pandemic has unprecedented implications for public health, social life, and the world economy. Because approved drugs and vaccines are limited or not available, new options for COVID-19 treatment and prevention are in high demand. To identify SARS-CoV-2-neutralizing antibodies, we analyzed the antibody response of 12 COVID-19 patients from 8 to 69 days after diagnosis. By screening 4,313 SARS-CoV-2-reactive B cells, we isolated 255 antibodies from different time points as early as 8 days after diagnosis. Of these, 28 potently neutralized authentic SARS-CoV-2 with IC(100) as low as 0.04 mug/mL, showing a broad spectrum of variable (V) genes and low levels of somatic mutations. Interestingly, potential precursor sequences were identified in naive B cell repertoires from 48 healthy individuals who were sampled before the COVID-19 pandemic. Our results demonstrate that SARS-CoV-2-neutralizing antibodies are readily generated from a diverse pool of precursors, fostering hope for rapid induction of a protective immune response upon vaccination. Twit Text FOAVip Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients ????Cell http://www.kidney.de/pget.php?&tw=1&pmid=32673567 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32673567 #FOAvip English Wikipedia <ref>{{Cite pmid|32673567}}</ref> Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients #MMPMID32673567 Kreer C; Zehner M; Weber T; Ercanoglu MS; Gieselmann L; Rohde C; Halwe S; Korenkov M; Schommers P; Vanshylla K; Di Cristanziano V; Janicki H; Brinker R; Ashurov A; Krahling V; Kupke A; Cohen-Dvashi H; Koch M; Eckert JM; Lederer S; Pfeifer N; Wolf T; Vehreschild MJGT; Wendtner C; Diskin R; Gruell H; Becker S; Klein F Cell 2020[Aug]; 182 (4): 843-854.e12 PMID32673567show ga The SARS-CoV-2 pandemic has unprecedented implications for public health, social life, and the world economy. Because approved drugs and vaccines are limited or not available, new options for COVID-19 treatment and prevention are in high demand. To identify SARS-CoV-2-neutralizing antibodies, we analyzed the antibody response of 12 COVID-19 patients from 8 to 69 days after diagnosis. By screening 4,313 SARS-CoV-2-reactive B cells, we isolated 255 antibodies from different time points as early as 8 days after diagnosis. Of these, 28 potently neutralized authentic SARS-CoV-2 with IC(100) as low as 0.04 mug/mL, showing a broad spectrum of variable (V) genes and low levels of somatic mutations. Interestingly, potential precursor sequences were identified in naive B cell repertoires from 48 healthy individuals who were sampled before the COVID-19 pandemic. Our results demonstrate that SARS-CoV-2-neutralizing antibodies are readily generated from a diverse pool of precursors, fostering hope for rapid induction of a protective immune response upon vaccination. |Antibodies, Neutralizing/genetics/immunology/*isolation & purification[MESH] |Antibodies, Viral/genetics/immunology/*isolation & purification[MESH] |B-Lymphocytes/immunology[MESH] |Betacoronavirus/immunology[MESH] |COVID-19[MESH] |Coronavirus Infections/*immunology[MESH] |Humans[MESH] |Immunoglobulin Variable Region/genetics/immunology[MESH] |Immunologic Memory[MESH] |Longitudinal Studies[MESH] |Pandemics[MESH] |Pneumonia, Viral/*immunology[MESH] |SARS-CoV-2[MESH]Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing(epmc).pdf DeepDyve Pubget Overpricing